Trace amines exist at levels far below dopamine or serotonin. One of them, tyramine, can still cause a genuine emergency, if you take certain antidepressants and eat the wrong food.
Part 8 of the Brain Chemistry series. New here? Start with Your Brain Is Not a Gas Tank, the short orientation that explains the four questions every article in this series answers.
What to know
- Trace amines are chemical cousins of dopamine, norepinephrine, and serotonin, made naturally by your body at much lower levels. Four matter here: beta-phenylethylamine, tyramine, tryptamine, and octopamine.
- Their receptor, called TAAR1, can influence dopamine and other monoamine systems in lab studies. It’s a promising research target, not a proven treatment.
- The one genuinely dangerous piece of this story: tyramine, found in some aged and fermented foods, can trigger a dangerous spike in blood pressure in people taking certain monoamine oxidase inhibitor (MAOI) antidepressants.
- Food and interaction rules for MAOIs are specific to each product. They must come from your prescriber or pharmacist, not a general internet list.
- Amphetamines work mainly through transporters and storage proteins that move dopamine and norepinephrine around, not primarily through TAAR1.
- Ulotaront, a TAAR1 drug once considered a promising new antipsychotic, looked good in an early trial. Two later phase 3 trials missed their goals. It is not FDA approved.
The short answer
Trace amines are low-abundance chemical messengers your body makes naturally. Beta-phenylethylamine comes from the amino acid phenylalanine, tyramine comes from tyrosine, tryptamine comes from tryptophan, and octopamine is made from tyramine. All four are broken down quickly by an enzyme family called monoamine oxidase, or MAO.
Their receptor, TAAR1, is found in many cells throughout the body, including in systems that also use dopamine, norepinephrine, and serotonin. In lab studies, activating TAAR1 can change how those systems’ transporters behave and how nerve cells fire. That made it an appealing idea for a new kind of antipsychotic that wouldn’t rely on blocking dopamine directly.
The clinical reality has been more complicated. Amphetamine-class medicines have well-established actions at dopamine and norepinephrine transporters and at a storage protein called VMAT2. TAAR1 may play some role, but it isn’t the whole mechanism. Meanwhile, the one truly dangerous trace-amine story is about tyramine: when a person takes certain MAO inhibitors, tyramine from food can build up and trigger a sharp, dangerous rise in blood pressure. No routine FDA-approved psychiatric medicine selectively targets TAAR1 as its main mechanism.
Beta-phenylethylamine. Made from phenylalanine and broken down quickly by MAO-B in many tissues. It activates TAAR1 in lab systems, but a low level doesn’t explain poor motivation or any specific symptom.
Tyramine. Made from tyrosine, and also found in some aged or fermented foods. Under normal conditions, MAO in the gut and liver keeps most dietary tyramine from ever reaching your bloodstream in meaningful amounts.
Tryptamine. Made from tryptophan. It’s related to serotonin, but it is not serotonin, and its direct human psychiatric role remains uncertain.
Octopamine. Made from tyramine. It’s a major signaling chemical in many invertebrates, but only a trace amine in humans, and there isn’t much direct human research on it.
These four are distinct molecules, not one interchangeable family. A finding about one doesn’t automatically apply to the others.
TAAR1: a promising target that hasn’t delivered yet
| Receptor or target | What it does, where it matters most, and why you might care |
|---|---|
| TAAR1 | What it does: Can change monoamine transporter behavior and nerve-cell firing in lab systems. Where it matters most: Dopamine, norepinephrine, and serotonin circuits. Why you might care: A promising non-dopamine-blocking antipsychotic target that hasn’t yet proven itself in large trials. |
| Dopamine transporter (DAT) | What it does: Moves dopamine back into the nerve cell. Where it matters most: Striatum, cortex, reward circuits. Why you might care: A well-established, direct target for amphetamine-class stimulants. |
| Norepinephrine transporter (NET) | What it does: Moves norepinephrine, and some dopamine, back into the nerve cell. Where it matters most: Central attention circuits and peripheral nerve endings. Why you might care: Important to attention medicines, and this is where the tyramine interaction happens. |
| MAO-A | What it does: Breaks down serotonin, norepinephrine, tyramine, and tryptamine. Where it matters most: Gut, liver, brain, and other tissues. Why you might care: Strong inhibition here is what creates the dangerous tyramine food interaction. |
| MAO-B | What it does: Breaks down beta-phenylethylamine and contributes to dopamine breakdown. Where it matters most: Brain and other tissues. Why you might care: Selectivity for this enzyme versus MAO-A varies by drug. |
Why tyramine can become dangerous
Under ordinary conditions, MAO in your gut and liver breaks tyramine down quickly, so very little from food ever reaches your circulation. That changes when someone takes a medicine that strongly inhibits the relevant MAO pathway. Absorbed tyramine can then build up, enter nerve endings through the norepinephrine transporter, and trigger a surge of norepinephrine release. The result can be a rapid, dangerous rise in blood pressure, a hypertensive crisis.
This is why food and interaction counseling is essential for anyone on a relevant MAO inhibitor. Tranylcypromine’s current label carries a boxed warning specifically about hypertensive crisis with significant tyramine intake.11 But the exact rules, which foods, how much, what to avoid entirely, differ by product. Get the specific plan from your prescriber or pharmacist. Do not rely on a general internet list, since it may not match the specific medicine, dose, or MAO enzyme it affects.
Amphetamines: TAAR1 is a piece, not the whole picture
Amphetamine-class medicines act at the dopamine and norepinephrine transporters and change how VMAT2, a protein that packages these chemicals into storage vesicles, handles them. This releases more dopamine and norepinephrine into circuits involved in attention and wakefulness. TAAR1 activation may contribute to this process, based mostly on cell and animal research, but it doesn’t replace the established transporter and vesicle mechanism as the main story.
Methylphenidate is a useful contrast: it blocks the dopamine and norepinephrine transporters too, but it isn’t an amphetamine-type substrate that gets pulled inside the nerve cell and pushes transmitter out the way amphetamine does. Two medicines used for the same diagnosis can work through genuinely different cellular steps.
| Medicine | What it does directly, used for, and main tradeoffs |
|---|---|
| Amphetamine and mixed amphetamine salts | What it does directly: Acts at dopamine and norepinephrine transporters and VMAT2; TAAR1 activation is supported mainly by cell and animal research. Used for: ADHD or narcolepsy, depending on the product. Main tradeoffs: Boxed warning for abuse, misuse, and addiction, including overdose and death; also insomnia, appetite loss, cardiovascular effects, and risk of psychosis or mania. |
| Lisdexamfetamine (Vyvanse) | What it does directly: Converted in the blood to dextroamphetamine, which then works like amphetamine. Used for: ADHD in adults and children 6+; moderate-to-severe binge-eating disorder in adults. Main tradeoffs: Same boxed warning for abuse, misuse, and addiction; cardiovascular, psychiatric, and growth effects in children. |
| Psychiatric MAO inhibitors | What it does directly: Inhibit MAO-A, MAO-B, or both, depending on the specific drug. Used for: Select depression treatment, product dependent. Main tradeoffs: Serious tyramine, serotonergic, and other drug interactions; requires a product-specific food and interaction plan. |
| Ulotaront (investigational) | What it does directly: TAAR1 agonist with additional serotonin receptor activity in lab testing. Used for: Investigational schizophrenia treatment, not approved. Main tradeoffs: Two phase 3 trials did not meet their main goal; full benefit and risk remain unresolved. |
| Ralmitaront (investigational) | What it does directly: TAAR1 partial agonist. Used for: Investigational schizophrenia treatment, not approved. Main tradeoffs: One trial was stopped for lack of expected benefit; a second trial did not beat placebo on its main outcome. |
The ulotaront lesson: a promising early trial is not an approval
Ulotaront looked genuinely promising in an early controlled schizophrenia trial. It drew attention because, unlike standard antipsychotics, it didn’t work by directly blocking dopamine D2 receptors. That early positive signal did not hold up: the sponsors later reported that two phase 3 trials, called DIAMOND 1 and DIAMOND 2, did not meet their primary goals.8 DIAMOND 1 showed no benefit at either dose tested.6 DIAMOND 2’s results were closer, and more complicated statistically, but the endpoint was still reported as not met.78
A related drug, ralmitaront, tells a similar cautionary story. One study of it was stopped early because it wasn’t showing the expected benefit.9 A second study finished, but neither dose beat placebo on the main outcome measured.10
Ulotaront development continued after these results, including registration of a later phase 3 study. That does not mean the drug is approved, effective, or available to patients. It’s also worth being clear that Breakthrough Therapy designation, a status the FDA can grant to speed up development of a promising drug, is not the same thing as FDA approval. Neither is a company continuing to run trials.
Can this be measured?
Researchers can measure trace amines in blood, urine, or tissue, but results vary enormously depending on diet, gut bacteria, MAO activity, and other medicines, which makes them unreliable for anything clinical. There is no routine PET scan used to select psychiatric treatment based on TAAR1 activity, and no commercial urine test for beta-phenylethylamine or tyramine that can tell you anything about what’s happening in your brain. Genetic tests don’t measure trace-amine levels either.
Rare inherited metabolic conditions can require specialized biochemical testing, but that’s a narrow medical situation, not something that generalizes to common psychiatric symptoms like poor focus or low motivation.
Which symptoms need a call, and which need urgent help
Track and mention at your next visit: mild, expected appetite or sleep changes that your prescriber already told you to watch for, as long as they remain manageable and safe.
Call the prescriber or pharmacist promptly: major insomnia, troubling appetite or weight change, repeated fast heart rate, or concerning blood pressure readings. Also call about new agitation, manic symptoms, hallucinations, or any question about an MAOI interaction. New agitation or confusion together with sweating, fever, diarrhea, tremor, or muscle rigidity after a relevant drug combination can signal serotonin syndrome and needs urgent evaluation.
Call Poison Control at 1-800-222-1222 for a suspected overdose, an accidental extra dose, or an uncertain combination involving a stimulant, an MAOI, a decongestant, or a supplement.
Call 911 now for seizure, loss of consciousness, severe breathing difficulty, chest pain, or signs of stroke. Also call for an extreme headache with severe blood pressure symptoms during MAOI treatment, which can signal a hypertensive crisis, or for rapidly worsening serotonin syndrome symptoms. For a suicidal or mental health crisis, call or text 988. If danger is immediate, call 911.
Your brain is not a gas tank, and neither focus nor motivation problems are proof of a trace-amine deficiency.
What to ask your prescriber
These are conversation starters, not instructions.
- Which symptom or function is this medicine meant to improve?
- What is its main target: a transporter, VMAT2, MAO, TAAR1, or something else?
- If this is an MAO inhibitor, where can I get the specific food and interaction plan for this exact product?
- What interactions matter with other antidepressants, decongestants, stimulants, caffeine, or supplements?
- Which sleep, appetite, heart-rate, or blood-pressure changes need a prompt call?
- What should I do if I miss a dose?
- Could stopping suddenly cause withdrawal, rebound, or a return of symptoms?
- How will we decide whether the benefit is meaningful enough to continue?
Bottom line
Trace amines exist at levels far below dopamine, norepinephrine, and serotonin, but low abundance doesn’t mean no importance. TAAR1 remains a genuinely promising research target that simply hasn’t delivered an approved treatment yet, and ulotaront’s path from early promise to missed phase 3 endpoints is a real lesson about how far a good early signal is from an approved medicine. The one piece of this story with immediate, practical stakes is the tyramine-MAOI interaction: it’s real, it’s dangerous, and the specific rules for avoiding it come from your prescriber or pharmacist, not a general list you find online.
Frequently asked questions
Does ADHD mean I have low beta-phenylethylamine or low TAAR1 activity?
No. ADHD isn’t diagnosed with a trace-amine test, and a medicine helping doesn’t prove a deficiency existed beforehand.
Does amphetamine work only by raising dopamine?
No. It acts at dopamine and norepinephrine transporters, changes how those chemicals are stored and released, and may engage TAAR1 to some degree. The exact contribution varies.
Can eating tyramine improve my mood?
No evidence supports using dietary tyramine as a way to treat yourself. Combined with certain MAO inhibitors, it can be dangerous instead.
Is ulotaront an approved medicine that treats psychosis without touching dopamine?
No. It’s investigational. Two phase 3 trials didn’t meet their main goal, and continuing to register new trials doesn’t equal approval.8
Can a urine phenylethylamine test tell me which medicine I need?
No. It samples what’s outside your brain and can’t report what TAAR1 is doing inside a living brain circuit.
Are phenethylamine supplements safer because they’re natural?
No. Being naturally occurring doesn’t establish a supplement’s purity, dose, benefit, or interaction safety.
Related reading on NP FADY
- Your Brain Is Not a Gas Tank (start here)
- Why Two Opposite Medicines Both Target Dopamine
- Focus, Alarm, and the Chemical Behind Both
- Drug Interactions to Know: Antidepressants, Alcohol, CBD, and More
References
1. IUPHAR trace-amine receptor family. Guide to Pharmacology. Accessed August 31, 2026. https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=64
2. Official nomenclature review of trace amine-associated receptors. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC2830119/
3. Comprehensive trace-amine review. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC4820462/
4. TAAR1 ligand review. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC8787759/
5. Comparative study of ulotaront and ralmitaront receptor activity. PubMed. Accessed August 31, 2026. PMID: 37549917
6. DIAMOND 1 phase 3 trial registry (ulotaront). ClinicalTrials.gov, NCT04072354. Accessed August 31, 2026. https://clinicaltrials.gov/study/NCT04072354
7. DIAMOND 2 phase 3 trial registry (ulotaront). ClinicalTrials.gov, NCT04092686. Accessed August 31, 2026. https://clinicaltrials.gov/study/NCT04092686
8. Sumitomo Pharma and Otsuka announce topline results for phase 3 DIAMOND 1 and DIAMOND 2 trials. Sponsor press release. Accessed August 31, 2026. https://otsuka-us.com/news/sumitomo-pharma-and-otsuka-announce-topline-results-phase-3-diamond-1-and-diamond-2-clinical
9. Ralmitaront negative-symptom study registry. ClinicalTrials.gov, NCT03669640. Accessed August 31, 2026. https://clinicaltrials.gov/study/NCT03669640
10. Ralmitaront acute-exacerbation study registry. ClinicalTrials.gov, NCT04512066. Accessed August 31, 2026. https://clinicaltrials.gov/study/NCT04512066
11. Tranylcypromine prescribing information, including boxed warning for hypertensive crisis. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=83942f11-e10c-4c2d-ad78-880e1886064d&type=display
12. Lisdexamfetamine (Vyvanse) prescribing information. DailyMed. Accessed August 31, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad
13. TAAR1 and drug-abuse review. PMC. Accessed August 31, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC9826737/
14. DEA drug scheduling reference. Drug Enforcement Administration. Accessed August 31, 2026. https://www.dea.gov/drug-information/drug-scheduling
This article is general education. It is not a diagnosis or a treatment plan. Do not start, stop, or change a medicine because of something you read here. Review every prescription, supplement, and substance with your prescriber or pharmacist.
If you or someone you know is in crisis
- Call 911 or go to your nearest emergency room for any life-threatening emergency.
- 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
- Crisis Text Line — text HOME to 741741.
- The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
- National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
- National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
- Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
- San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
- Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
- California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
- NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.